NEW YORK (GenomeWeb) – Editas Medicine is planning a public offering of 4 million shares of common stock, according to a document filed with the US Securities and Exchange Commission.

The Cambridge, Massachusetts-based firm said in a statement that it plans to use the proceeds to fund pre-clinical studies and clinical trials for CRISPR-based human therapies, specifically eye diseases, including Leber congenital amaurosis (LCA) 10.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

New Mexico is re-doing its proposed science education standards after criticism, the Associated Press reports.

Agbio executives say gene editing will speed up breeding efforts, according to the Wall Street Journal.

La Trobe University's Jenny Graves has won the $250,000 Prime Minister's Prize for Science, the Guardian reports.

In Cell this week: post-treatment changes to melanoma genome, multi-omics analysis of muscle-invasive bladder cancer, and more.